168. Thermal therapeutic options in the treatment of prostate cancer: Cellular responses to cryosurgery and hyperthermia

Klossner, Daniel P.; Clarke, Dominic M.; Bausta, John M.; Buskirk, Robert G. Van; Gage, Andrew A.; Baust, John G.

doi:10.1016/j.cryobiol.2006.10.169

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the observed in vitro-specific recovery, the region of incomplete cell death was still less than 2 mm at 72 h post-thaw, suggesting that only a 2 mm positive freeze margin is necessary with FrostBite . This is significantly smaller than the ≥5 mm positive freeze margin typically applied when using today’s argon-based JT cryodevices [ 24 , 69 , 83 , 84 , 87 ]. Correlation of isotherm and 72 h viability data demonstrated complete PANC-1 cell death in the range of −20 °C to −25 °C following a single 5 min freeze using the FrostBite EUS cryocatheter.…”

Section: Discussionmentioning

confidence: 92%

The Assessment of a Novel Endoscopic Ultrasound-Compatible Cryocatheter to Ablate Pancreatic Cancer

Baust,

Robilotto,

Raijman

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease that may be treated utilizing thermal therapies. Cryoablation is an effective, minimally invasive therapy that has been utilized for the treatment of various cancers, offering patients a quicker recovery and reduced side effects. Cryoablation has been utilized on a limited basis for the treatment of PDAC. With the recent reports on the success of cryoablation, there is a growing interest in the use of cryoablation as a standalone, minimally invasive procedure to treat PDAC. While offering a promising path, the application of cryoablation to PDAC is limited by current technologies. As such, there is a need for the development of new devices to support advanced treatment strategies for PDAC. To this end, this study investigated the performance of a new endoscopic ultrasound-compatible cryoablation catheter technology, FrostBite. We hypothesized that FrostBite would enable the rapid, effective, minimally invasive delivery of ultra-cold temperatures to target tissues, resulting in effective ablation via an endoscopic approach. Thermal properties and ablative efficacy were evaluated using a heat-loaded gel model, tissue-engineered models (TEMs), and an initial in vivo porcine study. Freeze protocols evaluated included single and repeat 3 and 5 min applications. Isotherm assessment revealed the generation of a 2.2 cm diameter frozen mass with the −20 °C isotherm reaching a diameter of 1.5 cm following a single 5 min freeze. TEM studies revealed the achievement of temperatures ≤ −20 °C at a diameter of 1.9 cm after a 5 min freeze. Fluorescent imaging conducted 24 h post-thaw demonstrated a uniformly shaped ellipsoidal ablative zone with a midline diameter of 2.5 cm, resulting in a total ablative volume of 6.9 cm3 after a single 5 min freeze. In vivo findings consistently demonstrated the generation of ablative areas measuring 2.03 cm × 3.2 cm. These studies demonstrate the potential of the FrostBite cryocatheter as an endoscopic ultrasound-based treatment option. The data suggest that FrostBite may provide for the rapid, effective, controllable freezing of cancerous pancreatic and liver tissues. This ablative power also offers the potential of improved safety margins via the minimally invasive nature of an endoscopic ultrasound-based approach or natural orifice transluminal endoscopic surgery (NOTES)-based approach. The results of this pre-clinical feasibility study show promise, affirming the need for further investigation into the potential of the FrostBite cryocatheter as an advanced, minimally invasive cryoablative technology.

show abstract

Section: Discussionmentioning

confidence: 92%

The Assessment of a Novel Endoscopic Ultrasound-Compatible Cryocatheter to Ablate Pancreatic Cancer

Baust,

Robilotto,

Raijman

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

show abstract

“…41 Experimentation has shown significant differences in outcome based on the current, the distance from heat source and on the type of tissue. [42][43][44][45] It is further suggested that some tumors may require a higher thermal dose, possibly achieved when approaching 90 C for a clinically relevant time scale.…”

Section: Radiofrequency Ablationmentioning

confidence: 99%

Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome

Baust

Rabin

Polascik

et al. 2018

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Background:Diverse thermal ablative therapies are currently in use for the treatment of cancer. Commonly applied with the intent to cure, these ablative therapies are providing promising success rates similar to and often exceeding “gold standard” approaches. Cancer-curing prospects may be enhanced by deeper understanding of thermal effects on cancer cells and the hosting tissue, including the molecular mechanisms of cancer cell mutations, which enable resistance to therapy. Furthermore, thermal ablative therapies may benefit from recent developments in computer hardware and computation tools for planning, monitoring, visualization, and education.Methods:Recent discoveries in cancer cell resistance to destruction by apoptosis, autophagy, and necrosis are now providing an understanding of the strategies used by cancer cells to avoid destruction by immunologic surveillance. Further, these discoveries are now providing insight into the success of the diverse types of ablative therapies utilized in the clinical arena today and into how they directly and indirectly overcome many of the cancers’ defensive strategies. Additionally, the manner in which minimally invasive thermal therapy is enabled by imaging, which facilitates anatomical features reconstruction, insertion guidance of thermal probes, and strategic placement of thermal sensors, plays a critical role in the delivery of effective ablative treatment.Results:The thermal techniques discussed include radiofrequency, microwave, high-intensity focused ultrasound, laser, and cryosurgery. Also discussed is the development of thermal adjunctive therapies—the combination of drug and thermal treatments—which provide new and more effective combinatorial physical and molecular-based approaches for treating various cancers. Finally, advanced computational and planning tools are also discussed.Conclusion:This review lays out the various molecular adaptive mechanisms—the hallmarks of cancer—responsible for therapeutic resistance, on one hand, and how various ablative therapies, including both heating- and freezing-based strategies, overcome many of cancer’s defenses, on the other hand, thereby enhancing the potential for curative approaches for various cancers.

show abstract

“…CA has been applied with a high degree of success in the treatment of skin, prostate, renal, liver, breast, and bone cancers, among others in both humans and animals [16][17][18][19][20][21][22][23]. To this end, several reports have demonstrated CA is as effective or superior to other cancer treatment options including surgery, radiotherapy and chemotherapy [12,[24][25][26]. In addition to being an effective cancer therapy, CA has the benefi t of low incidence of postoperative morbidity, low levels of pain, and is often utilized as a outpatient surgical approach [12,24,25].…”

mentioning

confidence: 99%

“…Numerous studies have detailed the effects of freezing in various cell systems demonstrating a differential response to similar freezing insults. Cell death due to freezing is not only a consequence of freeze rupture, but is also related to differential freeze-induced cell stress response which is believed to dictate therapeutic outcome [15,26,37]. Studies have also demonstrated that different molecular dispositions (sub-types) of the same cancer tissue type can respond differently CA [38][39][40].…”

mentioning

confidence: 99%

“…Studies have also demonstrated that different molecular dispositions (sub-types) of the same cancer tissue type can respond differently CA [38][39][40]. We have published studies using numerous cell models investigating this phenomenon [12,26,40]. For instance, Snyder, et al, have shown that breast cancer cells tolerate freezing to -15°C, whereas cardiac cells can withstand -30°C [41,42].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Characterization of canine mastocytoma cell response to cryoablation

Santucci¹,

Snyder²,

Buskirk³

et al. 2020

Int J Vet Sci Res

View full text Add to dashboard Cite

IntroductionMastocytoma represents 16%-21% of all skin cancers in dogs, making it the most common form of cutaneous cancer [1]. Mast cells are generated from hematopoietic stem cells, reside in connective tissues, and comprise a necessary component of the immune response system [2]. The cause of mast cell tumors (MCT's), whether benign or malignant, is unknown. The formation of cancerous MCT's occurs frequently in dogs with median age of onset between 8-9 years [3,4].One of the most predictive factors in MCT development and subsequent aggressiveness is breed. The majority of reports agree that boxers, Labrador retrievers, pugs, golden retrievers and bulldog breeds present with the highest incidence of . Though there are a number of factors which can infl uence prognosis, including breed, c-kit mutation status and age, many veterinarians agree that the most predictive factor in MCT aggressiveness is tumor grade. Though there Abstract Introduction: Mastocytoma Tumors (MCT) represent 16%-21% of all skin cancers in dogs, making it the most common form of cutaneous cancer. Solitary MCT are typically treated with wide surgical excision margins. While effective, MCT excision can cause the release of a large amount of histamine and other cytokines resulting in complications such as systemic shock or anaphylaxis. Treatments such as chemotherapy and radiotherapy have been considered to achieve complete remission. Cryoablation also represents a potential treatment option for MCT. While studies have shown cryoablation to be benefi cial for the treatment of numerous cancers in animals and humans, few studies have described the use of cryoablation to treat MCT's. The limited use of cryoablation is due to a number of factors including a lack of basic information pertaining to dosing (minimal lethal temperature) necessary to destroy MCT cancer. As such, in this study we conducted a series of in vitro studies using the C2 cell line and a pilot ex vivo fi ne needle aspirate tissue sample in an effort to detail the effects of freezing of canine MCT.Methods: Samples were exposed to temperatures ranging from -5°C to -25°C, modeling the periphery of a cryogenic lesion for 3, 5 and 10minutes, and various markers of viability and modes of cell death were assessed daily over a 3 days recovery period. Additionally, investigation of the involvement of apoptosis in MCT cell death fl owing freezing was conducted via immunoblotting and caspase inhibition studies.Results: Viability studies revealed the -25°C isotherm as the critical minimal lethal temperature to achieve complete MCT cell death regardless of hold time. As the hold time at temperatures of -15°C and -20°C increased from 3 to 10minutes the level of cell death was also found to increase. Fluorescence microscopy, caspase inhibition and protein analysis revealed necrosis to be the primary mode of cell death following freezing. These studies, however, also revealed a signifi cant level of apoptotic cell death post-freeze. Molecular analysis suggested that freezing to -15°C to -20°C re...

show abstract

168. Thermal therapeutic options in the treatment of prostate cancer: Cellular responses to cryosurgery and hyperthermia

Cited by 3 publications

References 0 publications

The Assessment of a Novel Endoscopic Ultrasound-Compatible Cryocatheter to Ablate Pancreatic Cancer

The Assessment of a Novel Endoscopic Ultrasound-Compatible Cryocatheter to Ablate Pancreatic Cancer

Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome

Characterization of canine mastocytoma cell response to cryoablation

Contact Info

Product

Resources

About